SiTime Corporation vs BIO-TECHNE Corp — how do they compare? SiTime Corporation trades at $592 (market cap $16.63B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: SiTime Corporation is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.45% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals.
| SITM | TECH | |
|---|---|---|
Market Cap | $16.63B | $11.16B |
Sector | Technology | Health |
52-Week High | $901.60 | $72.12 |
52-Week Low | $190.16 | $43.31 |
Enterprise Value | $15.84B | $11.24B |
Dividend Yield | — | 0.45% |
Signals from Pluang's Aura AI — not financial advice
SITM trades at $555.15, showing minimal daily movement with a bearish technical signal despite recent earnings beats. The company reported strong revenue growth and completed the acquisition of Renesas' timing business, but faces negative net income margins and high valuation multiples. Analyst consensus remains strongly bullish with a $825 price target, highlighting growth potential from AI infrastructure demand.
The outlook is mixed: robust revenue growth and strategic acquisitions support long-term potential, but profitability challenges and bearish technical indicators present near-term risks. Investors should weigh strong analyst confidence against execution risks and current negative margins.
No Aura AI signal available yet.
Trailing returns across standard periods
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →